Reaction Biology Corporation

reactionbiology.com

Reaction Biology Corp. (“RBC”) is a premier service provider for drug profiling, screening and early-stage drug discovery collaborations. Its proprietary HotSpot technology is an innovative platform for screening/profiling small molecules vs biological target assayable by radioisotope detection. For kinase and transferase enzymes in particular, such assays are the “gold standard”. RBC screens and profiles vs all major classes of epigenetic transferases via the radioisotope approach—HMTs, DNMTs, HATs, and also over 600 kinases. HotSpot assay substrates require no special modifications (e.g. biotin, fluorophors or other tags). Hence biologically relevant substrates may be used, including full nucleosomes, histone proteins or peptides. Since detection does not rely on antibodies, coupling enzymes or fluorescence, major causes of false positives, false negatives and compound interference are eliminated.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

news image

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More

Industrial Impact

FOUR NEW SETS OF PRE-CLINICAL DATA FURTHER EXPANDS THE EVIDENCE SUPPORTING ABELACIMAB

Anthos Therapeutics | July 14, 2022

news image

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK. "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becomi...

Read More

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

news image

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

news image

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More
news image

Industrial Impact

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More
news image

Industrial Impact

FOUR NEW SETS OF PRE-CLINICAL DATA FURTHER EXPANDS THE EVIDENCE SUPPORTING ABELACIMAB

Anthos Therapeutics | July 14, 2022

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK. "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becomi...

Read More
news image

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More
news image

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More